Nirmatrelvir–Ritonavir oral para Covid-19 en pacientes ambulatorios de mayor riesgo

Butler et al. (miércoles) estudiaron esta cuestión.

www.synapsesocial.com/papers/69ea386ec2ceeb8fbfae7e96 — DOI: https://doi.org/10.1056/nejmoa2502457

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes· 2024 · 5 citations
2. The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk· 2025 · 1 citations
3. An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19· 2021 · 1,892 citations
4. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial· 2021 · 315 citations
5. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial· 2021 · 80 citations